Latest news, Wikipedia summary, and trend analysis.
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
This topic is not currently in the ranking.
AN-788, also known as NSD-788 and IP-2018, is an experimental drug which was originated by NeuroSearch and is under development by Saniona for the treatment of major depressive disorder. It was also under development for anxiety disorders, but development for this indication was discontinued. The drug acts as a serotonin–dopamine reuptake inhibitor (SDRI). As of November of 2018, it is in an agreement for phase II clinical trials for major depressive disorder. As of September 2022, no recent development has been reported for major depressive disorder, but the drug is now in phase 2 clinical trials for erectile dysfunction.
Read more on Wikipedia →This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.